LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics


LogicBio Therapeutics, Inc. (LOGC)

Today's Latest Price: $8.26 USD

0.45 (-5.17%)

Updated Jan 27 6:55pm

Add LOGC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

LOGC Stock Summary

  • LogicBio Therapeutics Inc's stock had its IPO on October 19, 2018, making it an older stock than just 5.03% of US equities in our set.
  • With a price/sales ratio of 90.16, LogicBio Therapeutics Inc has a higher such ratio than 96.19% of stocks in our set.
  • Revenue growth over the past 12 months for LogicBio Therapeutics Inc comes in at 185.21%, a number that bests 96.64% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LogicBio Therapeutics Inc are VIE, LPTX, XFOR, CRIS, and BCRX.
  • Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.

LOGC Stock Price Chart Interactive Chart >

Price chart for LOGC

LOGC Price/Volume Stats

Current price $8.26 52-week high $11.60
Prev. close $8.71 52-week low $3.05
Day low $7.94 Volume 189,100
Day high $8.73 Avg. volume 124,218
50-day MA $7.67 Dividend yield N/A
200-day MA $7.17 Market Cap 262.55M

LogicBio Therapeutics, Inc. (LOGC) Company Bio


LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.


LOGC Latest News Stream


Event/Time News Detail
Loading, please wait...

LOGC Latest Social Stream


Loading social stream, please wait...

View Full LOGC Social Stream

Latest LOGC News From Around the Web

Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.

LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the expansion of the Company's research partnership with Children's Medical Research Institute (CMRI) to develop next-generation adeno-associated virus (AAV) vectors for a range of gene therapy and gene editing applications in the treatment of serious diseases of the liver and two other tissues.

Yahoo | January 7, 2021

LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET. Mr. Chereau will provide an overview of company operations including development of its proprietary genome editing platform GeneRide and its next-generation synthetic capsids. He will also participate in one-on-one sessions with investors during the virtual conference.

Yahoo | January 6, 2021

Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021. Matthias Jaffe, the current CFO at LogicBio, will step down at the end of the year and will remain a consultant to the Company during 2021.

Yahoo | December 22, 2020

What Kind Of Shareholders Hold The Majority In LogicBio Therapeutics, Inc.'s (NASDAQ:LOGC) Shares?

A look at the shareholders of LogicBio Therapeutics, Inc. ( NASDAQ:LOGC ) can tell us which group is most powerful...

Yahoo | December 18, 2020

Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics

Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics

Yahoo | December 4, 2020

Read More 'LOGC' Stories Here

LOGC Price Returns

1-mo 5.36%
3-mo 49.64%
6-mo 5.36%
1-year -16.65%
3-year N/A
5-year N/A
YTD 8.26%
2020 5.97%
2019 -30.77%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7913 seconds.